| http://www.w3.org/ns/prov#value | - There is also a potential benefit from an efficacy point of view, Bob Temple's in Richmond idea where you look for patients, particularly for difficult to evaluate conditions, and I would posit the GI disease is probably among the most difficult to evaluate the outcomes, where you have a run-in period on drug.
|
